ABCELY

Develops an innovative immunotherapy based on orally administered IgA monoclonal antibodies, targeting cancers of the digestive mucosa and endometriosis. Thanks to their polymeric structure, IgA antibodies are more avid for their target and recruit neutrophils more effectively. A unique platform for the identification, optimisation and production of these antibodies, offering an alternative to intravenous or subcutaneous IgG treatments.